TRPblue is developing a novel small molecule topical therapeutic that modulates crucial elements of peripheral nerve pain, itch, and inflammation.
Founded in 2017, TRPblue was spun out of Duke University and is based on the research of Dr. Wolfgang Liedtke, a scientist-physician, who made earlier discoveries in the arena of TRP ion channels and has contributed to this field significantly. An experienced management team has been assembled to advance TB16-8 into the clinic.